Bidirectional Changes in Myocardial 18 F-Fluorodeoxyglucose Uptake after Human Ventricular Unloading
Tiberiu A. Pana,Jainy Savla,Ingrid Kepinski,Adam Fairbourn,Aneela Afzal,Pradeep Mammen,Mark Drazner,Rathan M. Subramaniam,Chao Xing,Kathryn A. Morton,Stavros G. Drakos,Vlad G. Zaha,Hesham A. Sadek
DOI: https://doi.org/10.1161/circulationaha.121.056278
IF: 37.8
2022-01-01
Circulation
Abstract:HomeCirculationVol. 145, No. 2Bidirectional Changes in Myocardial 18F-Fluorodeoxyglucose Uptake After Human Ventricular Unloading Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBBidirectional Changes in Myocardial 18F-Fluorodeoxyglucose Uptake After Human Ventricular Unloading Tiberiu A. Pana, MBChB, MRes, Jainy Savla, MD, Ingrid Kepinski, BS, Adam Fairbourn, BS, Aneela Afzal, BS, Pradeep Mammen, MD, Mark Drazner, MD, Rathan M. Subramaniam, MBBS, BMedSc, MClinEd, MPH, PhD, MBA, Chao Xing, PhD, Kathryn A. Morton, MD, Stavros G. Drakos, MD, PhD, Vlad G. Zaha, MD, PhD and Hesham A. Sadek, MD, PhD Tiberiu A. PanaTiberiu A. Pana https://orcid.org/0000-0002-1423-8111 Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, United Kingdom (T.A.P.). Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Jainy SavlaJainy Savla Department of Internal Medicine/Cardiology, University of Washington, Seattle (J.S.). Search for more papers by this author , Ingrid KepinskiIngrid Kepinski Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Adam FairbournAdam Fairbourn Department of Radiology (A.F., R.M.S.); Search for more papers by this author , Aneela AfzalAneela Afzal https://orcid.org/0000-0002-0073-8166 Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Pradeep MammenPradeep Mammen https://orcid.org/0000-0001-5688-7091 Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Mark DraznerMark Drazner https://orcid.org/0000-0003-3054-4757 Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Rathan M. SubramaniamRathan M. Subramaniam Department of Radiology (A.F., R.M.S.); Search for more papers by this author , Chao XingChao Xing https://orcid.org/0000-0002-1838-0502 Eugene McDermott Center for Human Growth and Development (C.X.); Department of Bioinformatics (C.X.); Department of Population and Data Sciences (C.X.); Search for more papers by this author , Kathryn A. MortonKathryn A. Morton Department of Radiology and Imaging Sciences (K.A.M.), University of Utah School of Medicine, Salt Lake City. Search for more papers by this author , Stavros G. DrakosStavros G. Drakos https://orcid.org/0000-0002-1223-327X Division of Cardiovascular Medicine (S.G.D.), University of Utah School of Medicine, Salt Lake City. Search for more papers by this author , Vlad G. ZahaVlad G. Zaha Correspondence to: Vlad G. Zaha, MD, PhD, or Hesham A. Sadek, MD, PhD, 5323 Harry Hines Blvd. Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390. Email E-mail Address: [email protected] or E-mail Address: [email protected] https://orcid.org/0000-0003-4878-891X Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Harold C. Simmons Comprehensive Cancer Center (V.G.Z.); Advanced Imaging Research Center (V.G.Z.); Biomedical Engineering Program, Graduate School of Medical Sciences (V.G.Z.); Search for more papers by this author and Hesham A. SadekHesham A. Sadek Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Department of Molecular Biology (H.A.S.); Hamon Center for Regenerative Medicine (H.A.S.), University of Texas Southwestern Medical Center, Dallas. Search for more papers by this author Originally published10 Jan 2022https://doi.org/10.1161/CIRCULATIONAHA.121.056278Circulation. 2022;145:151–154Left ventricular assist devices (LVADs) are lifesaving interventions, especially as the number of advanced heart failure patients requiring circulatory support increases. LVADs decrease mechanical and metabolic demands, which may promote myocardial regeneration.1 Recent studies2,3 demonstrate appreciable functional recovery resulting in successful ventricular assist device explantation in a number of patients; typically, however, only a small percentage of patients with LVADs can fully recover.4 Therefore, it is important to define the fundamental mechanisms of myocardial recovery in response to LVAD. In the present study, we hypothesized that LVAD support stimulates myocardial regeneration as reflected by increased metabolic activity in previously nonviable regions of failing myocardium. Specifically, we set out to determine whether long-term LVAD mechanical unloading results in metabolic activation of quiescent myocardial regions by prospectively and longitudinally examining myocardial 18F-fluorodeoxyglucose (FDG) uptake in patients with end-stage heart failure after LVAD implantation.Patients 18 to 70 years of age with dilated or ischemic cardiomyopathy undergoing LVAD implantation within 3 to 6 months and with a preimplantation left ventricular ejection fraction ≤40% at the University of Texas Southwestern Medical Center were eligible to be included in the study. Exclusion criteria included: hypertrophic or radiation-induced cardiomyopathy, end-stage renal failure, hepatic cirrhosis, patients requiring right ventricular assist device support, those who developed LVAD complications (pump failure or LVAD thrombosis requiring exchange), and those with right ventricular failure requiring chronic inotropes. Pregnant patients were also excluded. This study was approved by the University of Texas Southwestern Medical Center Institutional Review Board (STU 102015-085) and was conducted in accordance with the Declaration of Helsinki (1964) and later amendments. The data that support the findings of this study are available from the corresponding author on reasonable request.A standard clinical myocardial viability positron emission tomography (PET) imaging protocol was used with injection of 0.15 mCi/kg of FDG and PET imaging performed 60 minutes afterward. Baseline FDG-PET scans were undertaken no more than 6 months from LVAD implantation, and follow-up FDG-PET scans were performed every 6 months until a maximum of 4 subsequent scans was achieved, the patient underwent heart transplantation, or the patient died. Image postprocessing was performed with MIM Software and the Matlab Image Processing Toolbox.Metabolic activity of myocardial areas with little or no metabolic activity at baseline regions of interest were defined as myocardial areas exhibiting less than the 5th percentile of FDG uptake on baseline scans. The distributions of pixel intensities were then compared between the regions of interests obtained from baseline and follow-up scans. Metabolic reactivation was quantified as the ratio between the areas under the intensity histograms at the follow-up scans that exceeded the 5th percentile thresholds and the total area under the intensity histogram of the quiescent areas at the baseline scan. Pairwise 2-sample Kolmogorov–Smirnov tests between baseline and each subsequent time point for each patient were performed to detect distributional changes. A total of 4 consenting eligible patients were included in the study, ranging from 31 to 59 years of age. Patients 1, 3, and 4 had been diagnosed with nonischemic cardiomyopathy, whereas patient 2 had been diagnosed with ischemic cardiomyopathy. Patients 2 and 3 had preexisting hypertension. All patients were receiving evidence-based heart failure disease–modifying pharmacological therapy. Of the 4 patients, 2 underwent 4 consecutive scans before cardiac transplant and 2 underwent 2 consecutive scans only. LVAD flow ranged between 3.4 to 5.9 L/min at baseline and remained relatively constant during the study period for each patient. In patients 1 and 2, LVAD speed was 2660 rotations per minute, whereas LVAD speeds in patients 3 and 4 were 9200 and 5500 rotations per minute, respectively. LVAD speeds remained constant during the study period for each patient.From baseline to follow-up scans, we found that 2 patients exhibited overall decreases in FDG uptake which predominantly affected the left ventricle lateral segments; 1 patient exhibited little change in FDG uptake during the study duration, and 1 patient exhibited overall increases in FDG uptake distributed across all myocardial segments (Figure [A and B]). Interestingly, all participants exhibited some degree of increase in FDG uptake in areas of previous metabolic inactivity at baseline, suggestive of possible myocardial regeneration. There was a significant degree of heterogeneity among participants, however, as a 1.87% to 23.80% increase in FDG uptake was observed in quiescent areas compared to baseline (Figure [C]). Inversely, analysis of FDG uptake in myocardial areas that were metabolically active at baseline showed that 2 patients exhibited significant decreases in FDG uptake, 1 exhibited increased FDG uptake, and 1 exhibited little change.Download figureDownload PowerPointFigure. Relative intensity of 18F-fluorodeoxyglucose (FDG) myocardial uptake by serial cardiac FDG positron emission tomography (FDG-PET) scans and displayed as polar maps. A, Diagrams showing the distribution of the different LV segments according to the American Heart Association 16-segment model are displayed over the polar maps (0 indicates no uptake; 100 indicates strong uptake). B, Polar maps displaying the relative change in the relative intensity of myocardial FDG uptake (–50 indicates a 50% decrease; +50 indicates a 50% increase) between baseline and follow-up time points, measured by serial cardiac FDG-PET scans. Red indicates regions with increased uptake from one time point to the next, whereas blue color indicates regions with decreased uptake from one time point to the next. Plots show the distribution of the different left ventricle segments according to the American Heart Association 16-segment model, and are displayed over the polar maps. C, Frequency histograms displaying the distribution of the FDG myocardial uptake in the areas of the myocardium exhibiting low FDG uptake (<5th percentile of the left ventricle FDG uptake levels at the baseline scan), exhibited as pairwise comparisons between the baseline and the follow-up (6, 12, 18 months) scans for each patient. The yellow dashed line indicates the 5th percentile of FDG uptake on the baseline scan for each patient. A rightward shift in the intensity distribution histogram represents an overall increase in FDG uptake, whereas a leftward shift represents an overall decrease in FDG uptake. The percentages displayed represent the ratio between the areas under the intensity histograms at the follow-up scans exceeding the 5th percentile thresholds and the area under the intensity histogram of the quiescent regions at the baseline scan. The horizontal axis represents the voxel-level relative intensity of FDG uptake normalized to the peak FDG uptake in metabolically active areas. The P values were obtained from pairwise 2-sample Kolmogorov–Smirnov tests for equality of distribution between baseline and each subsequent time point for each patient (P values <0.001). D, Frequency histograms displaying the total distribution of the FDG myocardial uptake exhibited as pairwise comparisons between baseline and follow-up (6, 12, 18 months) scans for each patient. A rightward shift in the intensity distribution histogram represents an overall increase in FDG uptake, whereas a leftward shift represents an overall decrease in FDG uptake.Although a recent, elegantly done study found no improvement in myocardial viability after a median 2.1 months of LVAD support,5 the present study is differentiated by a longer duration on LVAD which was previously shown to impact cardiomyocyte cell cycle reentry.1In conclusion, this prospective FDG-PET imaging study of 4 end-stage heart failure patients demonstrates that long-term mechanical unloading of the left ventricle is associated with bidirectional metabolic changes in the myocardium and a heterogenous, yet measurable, increase in viability of previously quiescent myocardial regions. However, a major limitation of this study is the small number of patients, and thus further studies are needed to determine the effect of mechanical unloading on myocardial viability.Article InformationData sharing: The data that support the findings of this study and research materials, as well as experimental procedures and protocols, are available from the corresponding author upon reasonable request.Sources of FundingThis work is supported by funds from the Center for Regenerative Science and Medicine at the University of Texas Southwestern and the Leducq Foundation (Redox Leducq). Dr Pana received the Academy of Medical Sciences INSPIRE International Scholarship 2019 to perform the research.Nonstandard Abbreviations and AcronymsFDG18F-fluorodeoxyglucoseLVADleft ventricular assist devicePETpositron emission tomographyDisclosures None.FootnotesThis manuscript was sent to Mauro Giacca MD, PhD for review by expert referees, editorial decision, and final disposition.For Sources of Funding and Disclosures, see page 152.Correspondence to: Vlad G. Zaha, MD, PhD, or Hesham A. Sadek, MD, PhD, 5323 Harry Hines Blvd. Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390. Email vlad.[email protected]edu or hesham.[email protected]eduReferences1. Canseco DC, Kimura W, Garg S, Mukherjee S, Bhattacharya S, Abdisalaam S, Das S, Asaithamby A, Mammen PP, Sadek HA. Human ventricular unloading induces cardiomyocyte proliferation.J Am Coll Cardiol. 2015; 65:892–900. doi: 10.1016/j.jacc.2014.12.027CrossrefMedlineGoogle Scholar2. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure.N Engl J Med. 2006; 355:1873–1884. doi: 10.1056/NEJMoa053063CrossrefMedlineGoogle Scholar3. Birks EJ, Drakos SG, Patel SR, Lowes BD, Selzman CH, Starling RC, Trivedi J, Slaughter MS, Alturi P, Goldstein D, et al.. Prospective multicenter study of myocardial recovery using left ventricular assist devices (RESTAGE-HF [Remission from Stage D Heart Failure]): medium-term and primary end point results.Circulation. 2020; 142:2016–2028. doi: 10.1161/CIRCULATIONAHA.120.046415LinkGoogle Scholar4. Wever-Pinzon O, Drakos SG, McKellar SH, Horne BD, Caine WT, Kfoury AG, Li DY, Fang JC, Stehlik J, Selzman CH. Cardiac recovery during long-term left ventricular assist device support.J Am Coll Cardiol. 2016; 68:1540–1553. doi: 10.1016/j.jacc.2016.07.743CrossrefMedlineGoogle Scholar5. Gupta DK, Skali H, Rivero J, Campbell P, Griffin L, Smith C, Foster C, Claggett B, Glynn RJ, Couper G, et al.. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device.J Heart Lung Transplant. 2014; 33:372–381. doi: 10.1016/j.healun.2014.01.866CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails January 11, 2022Vol 145, Issue 2Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.121.056278PMID: 35007159 Originally publishedJanuary 10, 2022 Keywordsprospective studiesfluorodeoxyglucose F18heart-assist devicespositron-emission tomographymyocardiumPDF download Advertisement SubjectsCardiomyopathyHeart FailureRemodeling
What problem does this paper attempt to address?
-
LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events
Eleanor F Gerhard,Lu Wang,Ramesh Singh,Stephan Schueler,Leonard D Genovese,Andrew Woods,Daniel Tang,Nicola Robinson Smith,Mitchell A Psotka,Sian Tovey,Shashank S Desai,Djordje G Jakovljevic,Guy A MacGowan,Palak Shah
DOI: https://doi.org/10.1016/j.healun.2021.08.001
Abstract:Background: Left ventricular assist devices (LVADs) mechanically unload the heart and coupled with neurohormonal therapy can promote reverse cardiac remodeling and myocardial recovery. Minimally invasive LVAD decommissioning with the device left in place has been reported to be safe over short-term follow-up. Whether device retention reduces long-term safety, or sustainability of recovery is unknown. Methods: This is a dual-center retrospective analysis of patients who had achieved responder status (left ventricular ejection fraction, LVEF ≥40% and left ventricular internal diastolic diameter, LVIDd ≤6.0 cm) and underwent elective LVAD decommissioning for myocardial recovery from May 2010 to January 2020. All patients had outflow graft closure and driveline resection with the LVAD left in place. Emergent LVAD decommissioning for an infection or device thrombosis was excluded. Patients were followed with serial echocardiography for up to 3-years. The primary clinical outcome was survival free of heart failure hospitalization, LVAD reimplantation, or transplant. Results: During the study period 515 patients received an LVAD and 29 (5.6%) achieved myocardial recovery, 12 patients underwent total device explantation or urgent device decommissioning, 17 patients underwent elective LVAD decommissioning, and were included in the analysis. Median age of patients at LVAD implantation was 42 years (interquartile range, IQR: 25-54 years), all had a nonischemic cardiomyopathy, and 5 (29%) were female. At LVAD implantation, median LVEF was 10% (IQR: 5%-15%), and LVIDd 6.6 cm (IQR: 5.8-7.1 cm). There were 11 hydrodynamically levitated centrifugal-flow (65%), and 6 axial-flow LVADs (35%). The median duration of LVAD support before decommissioning was 28.7 months (range 13.5-36.2 months). As compared to the turndown study parameters, 1-month post-decommissioning, median LVEF decreased from 55% to 48% (p = 0.03), and LVIDd increased from 4.8 cm to 5.2 cm (p = 0.10). There was gradual remodeling until 6 months, after which there was no statistical difference on follow-up through 3-years (LVEF 42%, LVIDd 5.6 cm). Recurrent infections affected 41% of patients leading to 3 deaths and 1 complete device explant. Recurrent HF occurred in 1 patient who required a transplant. Probability of survival free of HF, LVAD, or transplant was 94% at 1-year, and 78% at 3-years. Conclusions: LVAD decommissioning for myocardial recovery was associated with excellent long-term survival free from recurrent heart failure and preservation of ventricular size and function up to 3-years. Reducing the risk of recurrent infections, remains an important therapeutic goal for this management strategy.
-
Incidence, Outcomes, and Opportunity for Left Ventricular Assist Device Weaning for Myocardial Recovery
Shinobu Itagaki,Noah Moss,Nana Toyoda,Donna Mancini,Natalia Egorova,Gregory Serrao,Anuradha Lala,Sean P. Pinney,Percy Boateng,David H. Adams,Anelechi C. Anyanwu
DOI: https://doi.org/10.1016/j.jchf.2023.12.006
IF: 12.544
2024-01-26
JACC Heart Failure
Abstract:Background Myocardial recovery occurs in patients with advanced heart failure on left ventricular assist device (LVAD) support, but there is the premise that it is rare with uncertain results. Objectives The goal of this study was to investigate the incidence and consequence of LVAD explant after myocardial recovery. Methods Using the United Network for Organ Sharing registry, LVAD implants in the United States between 2005 and 2020 were tracked until death, transplantation, or explant for myocardial recovery. The cohort undergoing explant was followed up for heart failure relapse (defined as relisting followed by delisting due to death, being too ill, or transplantation; or second durable LVAD implant). Results Of 15,728 LVAD implants, 126 patients underwent explant for recovery, which only occurred in 55 (38%) of 145 implanting centers. The crude cumulative incidence was 0.7% at 2 years, whereas the incidence reached 4.7% among designated centers in the selected young nonischemic cohort. Of 126 explanted patients, 76 (60%) were subsequently delisted for sustained recovery. Heart failure relapsing had a relatively higher hazard in the early phase, with a 30-day incidence of 6% (7 of 126) but tapered following with the freedom rate of 72.5% at 4 years. Conclusions In the United States, LVAD explant for myocardial recovery was underutilized, leading to a very low incidence at the national level despite a realistic rate being achieved in designated centers for selected patients. With follow-up extending up to 4 years after explant, more than one-half were successfully removed and stayed off the waitlist, and approximately 70% were free from heart failure relapse events.
cardiac & cardiovascular systems
-
Cardiopulmonary Exercise Testing With Echocardiography to Assess Recovery in Patients With Ventricular Assist Devices
Jeffrey W Christle,Kegan J Moneghetti,Sebastien Duclos,Stephan Mueller,Yasbanoo Moayedi,Kiran K Khush,Francois Haddad,William Hiesinger,Jonathan Myers,Euan A Ashley,Jeffrey J Teuteberg,Matthew T Wheeler,Dipanjan Banerjee
DOI: https://doi.org/10.1097/MAT.0000000000001383
2021-10-01
Abstract:The left ventricular assist device (LVAD) is an established treatment for select patients with end-stage heart failure. Some patients recovered and are considered for explantation. Assessing recovery involves exercise testing and echo ramping on full and minimal LVAD support. Combined cardiopulmonary exercise testing with simultaneous echo ramping (CPET-R) has not been well studied. Patients were included if they had CPET within the previous 6 months, were clinically stable, and had an INR >2.0 on the day of examination. Patients had CPET-R on two occasions within 14 days: (a) with LVAD at therapeutic speed and (b) with LVAD at the lowest speed possible. Six patients were between 29 and 75 years (two female). One patient did not complete a turn-down test due to evidence of ischemia on initial CPET-R subsequently confirmed as a significant coronary artery stenosis on angiography. There were no significant differences in CPET or echo metrics between LVAD speeds. Two patients were explanted due to presumed LV recovery and remained event free for 30 and 47 months, respectively. Serial CPET-R seems safe and feasible for the evaluation of LV and global function and may result in improved clinical decision making for LVAD explantation.
-
Accuracy of predicting the duration of a surgical operation.
D. Laskin,A. Abubaker,R. Strauss
DOI: https://doi.org/10.1016/j.joms.2012.10.009
IF: 1.9
2013-02-01
Journal of Oral and Maxillofacial Surgery
Abstract:
-
Cardiological Challenges Related to Long-Term Mechanical Circulatory Support for Advanced Heart Failure in Patients with Chronic Non-Ischemic Cardiomyopathy
Michael Dandel
DOI: https://doi.org/10.3390/jcm12206451
2023-10-10
Abstract:Long-term mechanical circulatory support by a left ventricular assist device (LVAD), with or without an additional temporary or long-term right ventricular (RV) support, is a life-saving therapy for advanced heart failure (HF) refractory to pharmacological treatment, as well as for both device and surgical optimization therapies. In patients with chronic non-ischemic cardiomyopathy (NICM), timely prediction of HF's transition into its end stage, necessitating life-saving heart transplantation or long-term VAD support (as a bridge-to-transplantation or destination therapy), remains particularly challenging, given the wide range of possible etiologies, pathophysiological features, and clinical presentations of NICM. Decision-making between the necessity of an LVAD or a biventricular assist device (BVAD) is crucial because both unnecessary use of a BVAD and irreversible right ventricular (RV) failure after LVAD implantation can seriously impair patient outcomes. The pre-operative or, at the latest, intraoperative prediction of RV function after LVAD implantation is reliably possible, but necessitates integrative evaluations of many different echocardiographic, hemodynamic, clinical, and laboratory parameters. VADs create favorable conditions for the reversal of structural and functional cardiac alterations not only in acute forms of HF, but also in chronic HF. Although full cardiac recovery is rather unusual in VAD recipients with pre-implant chronic HF, the search for myocardial reverse remodelling and functional improvement is worthwhile because, for sufficiently recovered patients, weaning from VADs has proved to be feasible and capable of providing survival benefits and better quality of life even if recovery remains incomplete. This review article aimed to provide an updated theoretical and practical background for those engaged in this highly demanding and still current topic due to the continuous technical progress in the optimization of long-term VADs, as well as due to the new challenges which have emerged in conjunction with the proof of a possible myocardial recovery during long-term ventricular support up to levels which allow successful device explantation.
-
Tay-Sachs' and Sandhoff's diseases: the assignment of genes for hexosaminidase A and B to individual human chromosomes.
F. Gilbert,R. Kucherlapati,R. Creagan,M. Murnane,G. Darlington,F. Ruddle
DOI: https://doi.org/10.1073/PNAS.72.1.263
Abstract:The techniques of somatic cell genetics have been used to establish the linkage relationships of loci coding for two forms (A and B) of hexosaminidase (EC 3.2.1.30; 2-acetamido-2-deoxy-beta-D-glucoside acetamidodeoxyglucohydrolase) and to determine whether a structural relationship exists between these forms. In a series of human-mouse hybrid cell lines, hexosaminidase A and B segregated independently. Our results and those reported by other investigators are used to analyze the proposed structural models for hexosaminidase. We have also been able to establish a syntenic relationship between the gene locus responsible for the expression of hexosaminidase A and those responsible for mannosephosphate isomerase and pyruvate kinase-3 and to assign the gene for hexosaminidase B to chromosome 5 in man. There is thus a linkage between specific human autosomes and enzymes implicated in the production of lipid storage diseases.
-
A Case Series Of LVAD Explantation In Patients With Myocardial Recovery
Omar Al-Abboud,Aasim Afzal,Timothy George,Aldo Rafael,Nitin Kabra,David Rawitscher,Cesar Guerrero-Miranda
DOI: https://doi.org/10.1016/j.cardfail.2023.10.125
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Left Ventricular Assist Devices (LVADs) are durable mechanical support devices implanted in patients with refractory heart failure to improve survival and quality of life. In a certain subset of patients, we observe myocardial recovery significant enough to enable the removal of the LVAD. This case series describes the appropriate explanation of ten patients who received LVADs, and the criteria used to determine the appropriate times for LVAD removal. Methods A selection process was employed to identify patients who underwent LVAD explantation according to a predefined protocol. Patients meeting the minimum explant criteria were included. LVAD explantation was considered if the patient's left ventricular end-diastolic dimension (LVEDD) was less than 60 mm, left ventricular end-systolic dimension (LVESD) was less than 50 mm, and left ventricular ejection fraction (LVEF) was greater than 45%. Patients were required to have a pulmonary capillary wedge pressure of less than or equal to 15 mm Hg. As part of the diagnostic process, the patient underwent a right heart catheterization procedure where the LVAD was gradually ramped down to its minimum speed. This allowed for minimal flow through the device while relying on the heart's natural contractility to maintain a stable cardiac output. Patients meeting these criteria were evaluated by a multidisciplinary team of healthcare professionals to determine if LVAD removal was appropriate. Discussion The findings of this study suggest that LVAD removal according to a predefined protocol can be a viable treatment option for select patients with advanced heart failure who have demonstrated myocardial recovery. The study's criteria for LVAD explantation align with those of other studies, highlighting the importance of careful patient selection and close monitoring to ensure successful outcomes. The study also has several limitations, including its small sample size and retrospective nature. Future research with larger sample sizes and prospective study designs is necessary to confirm the findings and determine their generalizability. Conclusion This case series provides valuable insights into LVAD management and the appropriate timing for LVAD removal. LVAD explantation can be a safe and effective treatment option for select patients with advanced heart failure who have demonstrated myocardial recovery. Careful patient selection, close monitoring, and adherence to predefined criteria are essential to ensuring successful outcomes. The findings have the potential to impact clinical practice by guiding clinicians in their decision-making regarding LVAD management and offering hope to patients with advanced heart failure. Further research is needed to build on these findings and improve patient care and outcomes.
cardiac & cardiovascular systems
-
Initiation by the DNA-dependent RNA polymerase.
D. Anthony,E. Zeszotek,D. Goldthwait
DOI: https://doi.org/10.1073/PNAS.56.3.1026
1966-09-01
Abstract:The formation of the DNA-enzyme complex, step 1, can be inhibited by high ionic strength. When initiation occurs, a different DNA-enzyme complex is formed in the presence of purine nucleoside triphosphates which is not as easily dissociated by high ionic strength. The initiation complex can also be detected by a specially devised membrane assay. The exact nature of this complex is not established, but for its formation, a relatively high level of purine nucleotide is required. It will be shown that the association DNA-enzyme complex differs from the initiation DNAenzyme complex. The process of initiation is rate-limiting at low nucleoside triphosphate concentrations and purine nucleotides in relatively high concentrations overcome this limitation. In step 3, there is no differential effect of purine over pyrimidine nucleotides. The effect of purine nucleotides on initiation correlates with the observations of Maitra and Hurwitz' that the purine nucleoside triphosphates are the predominant 5'-terminal nucleotides found in RNA synthesized in vitro. Materials and Methods.-Nucleoside triphosphates (NTP) unlabeled were obtained from the Sigma Chemical Company (type 1). P32-NTP's were purchased from the International Chemical and Nuclear Corp., and H3-CTP was obtained from Schwarz BioResearch, Inc. A specific activity of 1,500-4,000 cpm/mjumole was employed. E. coli polymerase was prepared according to the procedure of Hurwitz2 and had a specific activity of 3,900-5,250 units/mg/hr. Two types of assays were employed to measure the synthesis of RNA. The first was the standard procedure as noted below Table 1. The second involved a membrane filter technique. Reaction mixtures were preincubated under the conditions noted in Table 2. The reactions were then temporarily terminated by filtration of the mixtures on 1.2-Mu M1illipore membranes. The DNA-enzyme complexes were retained while free enzyme or DNA passed through the filters.3 The complexes were washed with 0.05 M potassium maleate buffer pH 7.5, 0.001 M mercaptoethanol at 00, and the membranes were then introduced into reaction mixtures containing nucleoside triphosphates, one of which was isotopically labeled, plus metals, buffer, and mercapto-
-
Short-term mechanical unloading and reverse remodeling of failing hearts in children
Bhagyalaxmi Mohapatra,G Wesley Vick 3rd,Charles D Fraser Jr,Sarah K Clunie,Jeffrey A Towbin,Gianfranco Sinagra,Matteo Vatta
DOI: https://doi.org/10.1016/j.healun.2009.06.030
Abstract:Background: Mechanical support using a left ventricular assist device (LVAD) can lead to functional recovery of the myocardium in patients with end-stage heart failure (HF). Molecular remodeling, cytoskeletal disruption, and apoptosis activation are associated with abnormal gene expression in the failing ventricular myocardium of HF subjects and can normalize in response to medium- and long-term mechanical unloading in adults. However, there is little knowledge of the changes in gene expression after short-term mechanical support in children with HF. Methods: We evaluated left ventricular biopsies from 4 children with HF. The children had implantation of a continuous- or a pulsatile-flow LVAD for 8 to 16 days before undergoing heart transplantation. At the time of LVAD insertion and removal, we performed quantitative real-time polymerase chain reaction (QPCR) to study the expression of 326 genes encoding for structural, transcriptional, and signaling pathways proteins, and immunoblot analysis on dystrophin and apoptotic factors. Results: Short-term LVAD therapy significantly decreased brain natriuretic peptide (BNP) levels from pre-LVAD (3,584.5 +/- 378.3 pg/ml [95% CI]) to post-LVAD (447.5 +/- 52.7 pg/ml [95% CI]) in 2 patients in whom comparative BNP measurements were available. In addition, short-term LVAD therapy reduced HF and apoptosis markers, whereas it upregulated structural proteins, including dystrophin, as well as pro-hypertrophic and pro-inotropic markers. Furthermore, LVAD therapy normalized expression of genes involved in calcium homeostasis, cell growth, and differentiation. Conclusions: Our pilot study suggests that even short-term LVAD therapy in children with severe HF can reverse molecular remodeling. This favorable effect should be taken into consideration in eligible children with significant ventricular dysfunction.
-
Topographical and quantitative assessment of white matter injury following a focal ischaemic lesion in the rat brain.
Philippa S. Yam,James Patterson,D. I. Graham,T. Takasago,Deborah Dewar,James McCulloch
DOI: https://doi.org/10.1016/S1385-299X(98)00005-1
1998-06-01
Abstract:
-
Associated factors and percentage of cardiac recovery among patients using LVAD: a meta-analysis of 31 studies
E A Hasabo,B Isik,M S Bakr,M M F Eljack,D Neirokh,M Y Nosir,C Ayhan,H Alzomor,R Sawabi,S Sultan,K Caliskan,O Soliman
DOI: https://doi.org/10.1093/eurheartj/ehae666.1126
IF: 39.3
2024-10-30
European Heart Journal
Abstract:Introduction Patients with advanced heart failure use left ventricular assist devices (LVAD) to improve their outcomes and enhance the reverse remodeling of the heart. There has been no previous meta-analysis on the percentage of cardiac recovery after LVAD. This study aims to find the pooled percentage of cardiac recovery after LVAD. Methods A systematic search was done in PubMed, Scopus, Web of Science, Embase, and Cochrane from inception to December 2023. We used the relevant keywords to include studies that reported the percentage of people who achieved cardiac recovery after LVAD. The percentage of participants using LVAD and achieving cardiac recovery was extracted from the studies. RevMan 5.4 was used for meta-analysis. Results Thirty-two studies totaling 39215 patients were included. Different types of LVAD were used among participants. Across studies, different definitions for cardiac recovery were used, and the most used one is device explant following cardiac recovery and achieving left ventricular ejection fraction (LVEF) ≥ 40% after using LVAD. The pooled percentage of people who achieved cardiac recovery was 5.06%, 95% CI [4.17, 5.95], and the result was heterogeneous (I2 = 94%, p < 0.00001). Shorter duration of heart failure, female gender, younger age, presence of Implantable cardioverter-defibrillator (ICD) and low left ventricular end-diastolic diameter (LVEDD) were the most common mentioned factors associated with cardiac recovery. Conclusion Low cardiac recovery was found in patients using LVAD, and several factors were associated with cardiac recovery. Further action could be taken to improve the recovery among this population.
cardiac & cardiovascular systems
-
Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study
Keyur B Shah,Randall C Starling,Joseph G Rogers,Douglas A Horstmanshof,James W Long,Vigneshwar Kasirajan,Josef Stehlik,Joyce Chuang,David J Farrar,Jerry D Estep,ROADMAP Investigators
DOI: https://doi.org/10.1016/j.healun.2017.12.003
Abstract:Background: The ROADMAP study showed survival with improved functional status was better with left ventricular assist device (LVAD) therapy compared with optimal medical management (OMM) in ambulatory, non-inotrope-dependent (INTERMACS [IM] Profile 4 to 7) patients. To study more balanced cohorts and better define which patients may benefit from implantation of an LVAD, we re-evaluated the patients enrolled in ROADMAP when stratified by INTERMACS profile (Profile 4 and Profiles 5 to 7). Methods: The primary end-point (survival on original therapy with improvement in 6-minute walk distance ≥75 meters at 1 year), actuarial survival, adverse events (AEs) and health-related quality of life (HRQoL) were evaluated. Results: For INTERMACS Profile 4 (IM4), more LVAD patients met the primary end-point compared with OMM patients (40% vs 15%; odds ratio = 3.9 [1.2 to 12.7], p = 0.024), but there was no statistically significant difference for INTERMACS Profiles IM 5 to 7 (IM5-7). Event-free survival on original therapy at 2 years was greater for LVAD than for OMM patients in both IM4 (67% vs 28%; p < 0.001) and IM5-7 (76% vs 49%; p = 0.025) profile groups. Composite end-points of survival on original therapy with improved HRQoL or depression were better with LVAD than OMM in IM4, but not IM5-7. AEs trended higher in LVAD compared with OMM patients in both profile groups. Rehospitalization rates for LVAD vs OMM were similar between treatment arms in IM4 (82% vs 86%; p = 0.780), but were higher for LVAD in IM5-7 (93% vs 71%; p = 0.016). Conclusions: LVAD patients in IM4, but not IM5-7, are more likely to meet the primary end-point and have improvements in HRQoL and depression compared with OMM, even with AEs generally being more frequent. LVAD therapy with current technology may be beneficial in select IM4 patients, but can be deferred for most IM5-7 patients, who should be followed closely due to the high frequency of treatment failures.
-
Outcomes and Complications after Left Ventricular Assist Device Implantation
Grzegorz Wasilewski,Sylwia Wiśniowska-Śmiałek,Izabela Górkiewicz-Kot,Irena Milaniak,Michał Kaleta,Hubert Hymczak,Paulina Tomsia,Karol Wierzbicki
DOI: https://doi.org/10.1016/j.transproceed.2024.03.021
IF: 1.014
2024-05-13
Transplantation Proceedings
Abstract:Background Heart transplantation is the treatment of choice for selected patients with end-stage heart failure. Persistent donor organ shortage causes a growing demand for mechanical circulatory support not only as a bridge to transplantation but mainly as a destination therapy (DT). Methods The aim of the study was to analyze the indications, comorbidities, and complications during the follow-up of all patients undergoing left ventricular assist device (LVAD) implantation with at least 12 months of follow-up time in one of the most experienced clinics in Poland between 2015 and 2023. Results There were 125 individuals with LVAD implantation, from which 90 had full 12 months of follow-up (85 males – 94%, 5 females – 6%), with a median age of 58 (50.25-63.75) years. The median body mass index was 27.12 (25.27-29.68). The etiology of heart failure was ischemic (n = 44, 49%), dilated cardiomyopathy (n = 44, 49%), and others. Preoperative echocardiography revealed a mean LV ejection fraction of 13.8% and a median LV dimension of 7.55 (6.92-8.2) cm. In 61 patients (68%), imaging confirmed pulmonary hypertension. Thirty-four patients (38%) had diabetes and 16 (18%) were active smokers. Median follow-up was 30 (17.25-42) months, with the longest period being about 82 months. 40 (44%) patients had kidney failure before LVAD implantation, and in 43 cases (48%), we observed relevant, transient deterioration of kidney function. Almost all patients (n = 82, 91%) suffered from anemia (Hb <13 g/dL in males and <12 g/dL in females) in different periods after LVAD implantation due to perioperative bleeding, gastrointestinal bleeding or unknown causes. The lowest Hb level was observed in the first week after LVAD implantation in 53 cases (58%). Median red cell concentrate transfusion demand before the discharge after surgery was 6 (2-8, 5) units. Conclusions Appropriate selection of candidates and timing of LVAD implantation are critical for improved outcomes of DT. Anemia and kidney failure are the most frequent follow-up complications. Improved results and increased applicability and durability of LVADs have established this treatment option as an excellent alternative for patients with end-stage heart failure.
immunology,surgery,transplantation
-
Interdigitating cells and dendritic cells of the mouse identified by monoclonal antibodies: interaction with lymphocyte subsets.
M. Breel,R. Mebius,Georg Kraal
DOI: https://doi.org/10.1007/978-1-4684-5535-9_113
Advances in experimental medicine and biology
Abstract:
-
Patient-specific in silico prediction of outcomes of partial continuous-flow LVAD treatment in peripartum cardiomyopathy
Juliet Nagawa,Kevin L Sack,Ngaka John Nchejane,Yawovi Dodzi Motchon,Mazin S Sirry,Sarah Kraus,Neil H Davies,Ntobeko AB Ntusi,Thomas Franz
DOI: https://doi.org/10.1101/2024.09.18.24313803
2024-09-19
Abstract:Patients with severe peripartum cardiomyopathy (PPCM) often receive mechanical circulatory support with good outcomes. However, the mechanisms underlying the functional improvements are poorly understood. This study investigated the effects of partial, continuous-flow left ventricular assist device (LVAD) support on cardiac function and mechanics in patients with PPCM of different severity. Patient-specific biventricular finite element models of six PPCM patients (four recovered, two non-recovered) were developed from magnetic resonance images and combined with a circulatory system model, including variable LVAD support. Ventricular function and myocardial mechanics were predicted, and changes due to LVAD support were quantified. The LVAD support decreased myofiber stress and increased ejection fraction (EF) of the LV. EF increased steadily (two patients), fluctuated (two patients), or peaked before a steady decrease (two patients) with increasing LVAD speed. Improvement due to LVAD support was greater for PPCM patients with higher disease severity than those with lower disease severity. The LVAD and native LV jointly generated stroke volume (SV) in four patients, and the LV contribution diminished with increasing LVAD speed. In the two patients with the lowest EF, the LVAD was the sole source of SV. The improvement of cardiac function and mechanics due to LVAD support in PPCM exceeds that reported for chronic heart failure due to ischemia. However, the predicted variability of the LVAD benefits with PPCM severity and mechanical support level suggests the need and potential for further studies to guide clinicians in selecting personalised treatment parameters required for optimised LVAD therapy for each PPCM patient.
-
Qualitative Evaluation of Suicide and Overdose Risk Assessment Procedures Among Veterans in Substance Use Disorder Treatment Clinics
Linda L. Webster,Anna Eisenberg,A. Bohnert,Felicia Kleinberg,M. Ilgen
DOI: https://doi.org/10.1080/13811118.2012.695273
2012-07-01
Archives of Suicide Research
Abstract:The objective of this study was to examine risk assessment practices for suicide and unintentional overdose to inform ongoing care in substance use disorder clinics. Focus groups were conducted via telephone among a random sample of treatment providers (N = 19) from Veterans Health Administration substance use disorder clinics across the nation. Themes were coded by research staff. Treatment providers reported consistent and clear guidelines for risk assessment of suicide among patients. Unintentional overdose questions elicited dissimilar responses which indicated a lack of cohesion and uniformity in risk assessment practices across clinics. Suicide risk assessment protocols are cohesively implemented by treatment providers. Unintentional overdose risk, however, may be less consistently assessed in clinics.
-
Global Lipidomic and Metabolomic Uncovers Blood Signatures of Left Ventricular Assist Devices for Heart Failure
Yu Zhang,Na Zhang,Hao Chen,Heping Li,XiaoYu Xu,Xuman Zhang,Hai-Tao Hou,Zhifu Han,Guo-Wei He
DOI: https://doi.org/10.1101/2024.11.19.24317588
2024-11-20
Abstract:Abstract
Background: The left ventricular-assist device (LVAD) significantly improves the health of patients with chronic advanced heart failure (HF); however, its underlying molecular mechanisms remain unclear. This study aimed to develop an integrated plasma pseudo-targeted lipidomic and untargeted metabolomic strategy to provide insight into the early postoperative changes that occur in the global blood metabolome profile and determine whether these changes can be used to screen patients for LVAD installation.
Methods: Data was collected from 20 pairs of patients with HF before and after LVAD surgery and compared with 36 healthy subjects. Plasma metabolomic and lipidomic profiles were established by liquid chromatography-mass spectrometry and analyzed by multivariate statistics.
Results: A total of 49 lipids showed significant recovery after LVAD pump loading compared with before pump loading. Moreover, 144 differential metabolites and 21 pathways were identified from healthy control and patients with HF. Among which, 33 metabolites were differentially regulated between pre and post-LVAD samples (p < 0.05, FC > 2). Further analysis revealed differential regulation in two key pathways: fatty acid metabolism and methionine metabolism. Simultaneously, we identified S-adenosylmethionine, L-methionine, FFA (14:1), and FFA (16:1) as potential diagnostic markers for the prediction of LVAD efficacy in HF. In three postLVAD patients who died within one year, we observed a decrease in SM (24:0) and SM (22:0) immediately before LVAD implantation, indicating that these metabolites may predict a poor outcome. Furthermore, we demonstrated that PS (18:1/20:4) and canavaninosuccinate were significantly attenuated in postLVAD patients.
Conclusions: Our findings provide preliminary evidence that LVAD therapy is associated with changes in the metabolomic and lipidomic profiles of patients with HF. It highlights the potential use of metabolomics as a tool to stratify LVAD patients based on the risk of adverse events. These findings may help to guide patient selection for advanced HF therapies and identify new HF therapeutic targets.
-
Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats.
K. de Mari,L. Maynard,A. Sanquer,B. Lebreux,H. Eun
DOI: https://doi.org/10.1111/j.1939-1676.2004.tb02570.x
Journal of Veterinary Internal Medicine
Abstract:The clinical efficacy of a recombinant feline interferon, rFeIFN-omega, was evaluated for the treatment of cats presented with clinical signs associated with feline leukemia virus (FeLV) infection and FeLV/feline immunodeficiency virus (FIV) coinfection in the field. In this multicentric, double-blind, placebo-controlled trial, 81 cats meeting the inclusion criteria were randomly placed into 2 groups and treated subcutaneously with rFelFN-omega (1 million [M]U/kg per day) or placebo once daily for 5 consecutive days in 3 series (day 0, 14, 60). The cats were monitored for up to 1 year for clinical signs and mortality. During the initial 4-month period, interferon (IFN)-treated cats (n = 39) had significantly reduced clinical scores compared with placebo (n = 42), with all cats having received concomitant supportive therapies. Compared with the control, the IFN-treated group showed significantly lower rates of mortality: 39% versus 59% (1.7-fold higher risk of death for controls) at the 9-month time point and 47% versus 59% (1.4-fold higher risk of death for controls) at the 12-month time point. The IFN treatment was associated with minor but consistent improvement in abnormal hematologic parameters (red blood cell count, packed cell volume, and white blood cell count), apparently underlying the positive effects of IFN on clinical parameters. These data demonstrate that rFeIFN-omega initially has statistically significant therapeutic effects on clinical signs and later on survival of cats with clinical signs associated with FeLV infection and FeLV/FIV coinfection.
-
Computed Tomography–Estimated Right Ventricular Function and Exercise Capacity in Patients with Continuous-Flow Left Ventricular Assist Devices
M. H. Jung,F. Gustafsson,K. Kofoed,M. Elming,K. Rossing,P. Sigvardsen,K. Mirza
DOI: https://doi.org/10.1097/MAT.0000000000000925
2020-01-01
Abstract:Using four-dimensional (4D) cardiac computed tomography (CCT) scans at rest and immediately after exercise, we examined the right heart chamber sizes and systolic function and its association with exercise capacity in left ventricular assist device (LVAD) recipients. Fifteen patients with HeartMate (HM) II or 3 underwent echocardiography and maximal cardiopulmonary exercise test. Subsequently, contrast-enhanced CCT scans were performed at rest and immediately after two minutes of supine 25 Watt ergometer bike exercise. Patients were (60 ± 12 years of age) 377 ± 347 days postimplant. Peak oxygen uptake (pVO2) was 15 ± 5 ml/kg/min. LV ejection fraction measured by echocardiography was 15 ± 9%. Pump speed was 9500 ± 258 in HM II and 5518 ± 388 rpm in HM 3 recipients. Resting right atrial ejection fraction (RAEF) was 18 ± 9%, and right ventricular ejection fraction (RVEF) was 36 ± 8%. During stress, RAEF was 19 ± 10%, and RVEF was 37 ± 8%. RAEF and RVEF did not correlate significantly with pVO2 at rest or during stress. Resting-RAEF and stress RAEF correlated significantly: r = 0.87, p < 0.01 as did resting RVEF and stress RVEF: r = 0.76, p < 0.01. In conclusion, resting-EF predicted stress-EF for both RA and RV in patients with an LVAD. Neither RVEF nor RAEF correlated with pVO2.
Medicine,Engineering
-
Low Molecular Weight Heparin and Aspirin for Recurrent Pregnancy Loss: Results from the HepASA Trial
H. Carp
DOI: https://doi.org/10.3899/jrheum.090310
2010-01-01
Abstract:To the Editor:
Laskin, et al 1 claim that low molecular weight heparin and aspirin (LMWH/ASA) did not confer incremental benefit compared to ASA alone in women with recurrent pregnancy loss and either autoantibodies or a coagulation abnormality. However, the inclusion criteria were so wide as to preclude any significant results. Patients with 2 unexplained consecutive pregnancy losses prior to 32 weeks’ gestation have an 80% chance of a subsequent live birth. No treatment will significantly increase the live birth rate over 80%. Blighted ova resulting in first-trimester abortions and pregnancy losses at 32 weeks starting with …